Here, the additive effect of PARP inhibition (using olaparib) in combination with CHK1 inhibitor PF00477736 in reducing radiation-induced survival of two HPV-positive HNSCC cell lines has been shown[54]. The gene discussed is PARP1; the disease is head and neck squamous cell carcinoma.